SCHEMBL22922802

SCHEMBL22922802

CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NAA50 Q9GZZ1 1/20 0.42
▸ APLNR P35414 1/20 0.41
▸ MAPK8 P45983 1/20 0.40
▸ MAPK9 P45984 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ KEAP1 Q14145 1/20 0.39
▸ NMUR2 Q9GZQ4 1/20 0.38
▸ NMUR1 Q9HB89 1/20 0.38
▸ KDM1A O60341 3/20 0.38
▸ GRPR P30550 1/20 0.37
▸ CALCRL Q16602 1/20 0.37
▸ OXTR P30559 1/20 0.37
▸ RAMP3 O60896 4/20 0.37
▸ CALCR P30988 4/20 0.37
▸ MAOB P27338 1/20 0.37
▸ KDM5A P29375 1/20 0.37
▸ KDM1B Q8NB78 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26391856 0.96 APLNR (0.38) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL22018362 0.92 FAP (0.38) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL22922838 0.91 MAPK8 (0.43) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL23871517 0.91 FAP (0.38) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL22922937 0.88 KEAP1 (0.40) NAA50MAPK8MAPK9MAPK10KEAP1
SCHEMBL29308497 0.88 FAP (0.36) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL29308274 0.85 MAPK8 (0.34) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL29308489 0.85 NAA50 (0.39) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL29308229 0.85 CTSD (0.37) NAA50APLNRMAPK8MAPK9MAPK10
SCHEMBL22019459 0.84 APLNR (0.49) NAA50APLNRMAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210024577-A1 NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT YUYU PHARMA, INC. (KR) 2021-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024577-A1 NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT VIP, NGLY1, PROKR1 NAA50 4230/4885APLNR 279/4885MAPK8 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback